일본뇌염 예방접종 후 면역원성 및 중화항체 지속률에 관한 조사:전향적 다기관 코호트 연구
Immunogenicity and Protective Effectiveness of Japanese Encephalitis Vaccine : A Prospective Multicenter Cohort Study
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
목적: 일본뇌염 백신의 면역원성 및 중화항체 지속률을 평가하여 일본뇌염 예방 사업을 위한 토대를 제공하고자 하였다. 방법: 국내 6개 대학병원에 입원한 2-6세의 어린이 중 기초접종력이 확인된 170명을 대상으로 기초접종 완료 경과 기간에 따른 중화항체가를 조사하였다. 결과: 총 170명 중 불활성화 백신 접종군 103명, 생백신 접종군 64명, 교차접종군 3명이었다. 항체검사까지의 기간은 불활성화 백신 17.5개월, 생백신 21.0개월이었고 모두 일본뇌염 방어가 가능한 항체가를 보여 불활성화 백신 322, 생백신 266이었다. 추가접종 후 항체역가 변화는 1-4개월에 가장 높았고 이후 서서히 떨어지는 경향을 보였다. 결론: 불활성화 백신과 생백신의 면역원성과 중화항체 지속률에는 차이가 없고 두 백신 모두 일본뇌염 예방을 위한 적절한 수준의 면역원성을 갖고 있었다. 향후 대규모 표본을 대상으로 더 많은 연구가 필요하다.
Abstract
Purpose: This study aimed to study the antibody response of Japanese encephalitis vaccination in children using different kinds of vaccines (inactivated vaccine, live attenuated vaccine or interchanged) and evaluate the effectiveness of the vaccines to provide the basis of efficient immunization schedule of Japanese encephalitis. Methods: Measurement of the neutralization antibody (NTAb) titers following Japanese encephalitis vaccination using different vaccines for 170 children, 2-6 year of age, who visited six university hospitals and are confirmed by immunization records. Results: Among 170 children who were given primary immunization on Japanese encephalitis, 103 children were given inactivated vaccine, 64 children were given live attenuated vaccine and 3 children were given interchangeably. NTAb titers were more than 1:10 in all children of three groups. The geographic mean antibody titer was 322 in inactivated vaccine group and 266 in live attenuated vaccine group. However, there was no significant difference between two groups. In both groups, the NTAb titer showed the peak at 1-4 months after the third immunization and declined. The NTAb titers of three children who were given two kinds of vaccines alternately were 1:135, 1:632, and 1:2511, respectively. Conclusion: According to the results of this study in children younger than 6 years old, there is no significant difference in effectiveness between inactivated and live attenuated vaccines. However, further studies for the changes of antibody titers for a longer period of time on larger population are required.
참고문헌 (21)
- Chambers TJ, "Flavivirus genome organization, expression, and replication", Annu Rev Microbiol, 44, pp.649~688 (1990)
- Erlanger TE, "Past, present, and future of Japanese encephalitis", Emerg Infect Dis, 15, pp.1~7 (2009)
- Endy TP, "Japanese encephalitis virus: ecology and epidemiology", Curr Top Microbiol Immunol, 267, pp.11~48 (2002)
- Halstead SB, "Japanese encephalitis vaccines, In Vaccines", pp.312~351 (2013), Elsevier Saunders Co
- Department of Health, "Japanese encephalitis, In Immunisation against infectious disease", pp.201~208 (2013), TSO Co
- 홍영진, "일본뇌염백신: 국제적 현황과 우리나라 현황", Pediatric Infection and Vaccine, 15(2), pp.108~114 (2008), 대한소아감염학회
- Sohn YM, "The background and changes of inactivated Japanese encephalitis vaccine schedule", Korean J Pediatr Infect Dis, 7, pp.56~70 (2000)
- Calisher CH, "Togaviridae and Flaviviridae: the alphaviruses and Flaviviruses, In Laboratory diagnosis of infectious diseases", pp.414~434 (1988), Springer-Verlag
- Korea Center for Disease Control and Prevention, "Japanese encephalitis in Korea since 2001", Public Health Weekly Report, 1, pp.289~292 (2008)
- "Activity of Japanese encephalitis virus in the Republic of Korea" (2012)[URL]
- Hsu TC, "A completed field trial for an evaluation of the effectiveness of mouse-brain Japanese encephalitis vaccine, In Immunization for Japanese Encephalitis", pp.285~291 (1972), Excerpta Medica
- Hoke CH, "Protection against Japanese encephalitis by inactivated vaccines", N Eng J Med, 319, pp.608~614 (1988)
- Yang SE, "The efficacy of mouse-brain inactivated Nakayama strain Japanese encephalitis vaccine-results from 30 years experience in Taiwan", Vaccine, 24, pp.2669~2673 (2006)
- Poland JD, "Evaluation of the potency and safety of inactivated Japanese encephalitis vaccine in US inhabitants", J Infect Dis, 161, pp.878~882 (1990)
- Sohn YM, "Report of study result regarding effective level of antibody persistence rate after Japanese B encephalitis vaccination", Korean J Pediatr, 38, pp.730~731 (1995)
- Oya A, "Japanese encephalitis vaccine", Acta Paediatr Jpn, 30, pp.175~184 (1988)
- Aihara H, "Establishment and characterization of Japanese encephalitis virus-specific, human CD4(+) T-cell clones: flavivirus cross-reactivity, protein recognition, and cytotoxic activity", J Virol, 72, pp.8032~8036 (1998)
- Van der Vliet D, "Long-term seroprotection against Japanese encephalitis using an inactivated vaccine (Jevax)", Med Trop (Mars), 70, pp.155~157 (2010)
- Ku CC, "Homologous and heterologous neutralization antibody responses after immunization with Japanese encephalitis vaccine among Taiwan children", J Med Virol, 44, pp.122~131 (1994)
- Hennessy S, "Effectiveness of live-attenuated Japanese encephalitis vaccine (SA 14-14-2): a case-control study", Lancet, 347, pp.1583~1586 (1996)
- Sohn YM, "Primary and booster immune responses to SA 14-14-2 Japanese encephalitis vaccine in Korean infants", Vaccine, 17, pp.2259~2264 (1999)